Tumor-specific, 'signature' mutations of p53 have been identified in several cancers. The molecular basis of these tissue-specific selections has been poorly understood. A recent report sheds light on this issue by identifying the molecular basis of one such signature mutation found in adrenal cortical carcinomas.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
TP53p.R337H is a conditional cancer-predisposing mutation: further evidence from a homozygous patient
BMC Cancer Open Access 09 April 2013
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hainaut, P. & Hollstein, M. The p53 tumor suppressor gene: The first ten thousand mutations. Adv. Cancer Res . 77, 81–137 (2000).
Malkin, D. et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250, 1233–1238 (1990).
DiGiammarino, E.L. et al. A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. Nature Struct. Biol. 9, 12–16 (2002).
Ribeiro, R.C. et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc. Natl. Acad. Sci. USA 98, 9330–9335 (2001).
Lomax, M.E., Barnes, D.M., Hupp, T.R., Picksley, S.M. & Camplejohn, R.S. Characterization of p53 oligomerization domain mutations isolated from Li–Fraumeni and Li–Fraumeni like family members. Oncogene 17, 643–649 (1998).
Jeffrey, P.D., Gorina, S. & Pavletich, N.P. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science 267, 1498–1502 (1995).
Spencer, S.J., Mesiano, S., Lee, J.Y. & Jaffe, R.B. Proliferation and apoptosis in the human adrenal cortex during the fetal and perinatal periods: implications for growth and remodeling. J. Clin. Endocrinol. Metab. 84, 1110–1115 (1999).
Birch, J.M. et al. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 20, 4621–4628 (2001).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hainaut, P. Tumor-specific mutations in p53: The acid test. Nat Med 8, 21–23 (2002). https://doi.org/10.1038/nm0102-21
Issue Date:
DOI: https://doi.org/10.1038/nm0102-21
